| Worth Audiology Pllc | |
|
10512 N 110th East Ave Ste 220, Owasso, OK 74055-6638 | |
| (918) 516-1919 | |
| (539) 664-7792 |
| Full Name | Worth Audiology Pllc |
|---|---|
| Type | Facility |
| Speciality | Audiologist |
| Location | 10512 N 110th East Ave Ste 220, Owasso, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861159964 | NPI | - | NPPES |
| 200327260A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| Provider Name | Jessica L Worth |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1962792960 PECOS PAC ID: 4587820782 Enrollment ID: I20120719000627 |
News Archive
Anacor Pharmaceuticals announced today that it has entered into a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation to provide up to $30 million in capital. Anacor used $6.6 million to repay the remaining obligations under its loan agreement with Lighthouse Capital Partners and expects to use the remainder of the capital to fund development activities related to AN2690, AN2728 and AN2898.
Taro Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has informed the Company that after a February 2011 re-inspection of its Canadian manufacturing facility, the site has an acceptable regulatory status. Therefore, the issues noted in the February 5, 2009 warning letter are considered to be resolved.
Electronic health records have the potential to reduce the incidence of medical errors, duplication of tests, and delays in treatment.
7 in 10 UK chronic pain sufferers delayed seeking medical advice during the COVID-19 pandemic, leaving them feeling increased levels of stress, anxiety and worry, new research from Boston Scientific has revealed.
› Verified 7 days ago
| Provider Name | Morgan Greiner |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1942868617 PECOS PAC ID: 2860720851 Enrollment ID: I20190829001125 |
News Archive
Anacor Pharmaceuticals announced today that it has entered into a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation to provide up to $30 million in capital. Anacor used $6.6 million to repay the remaining obligations under its loan agreement with Lighthouse Capital Partners and expects to use the remainder of the capital to fund development activities related to AN2690, AN2728 and AN2898.
Taro Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has informed the Company that after a February 2011 re-inspection of its Canadian manufacturing facility, the site has an acceptable regulatory status. Therefore, the issues noted in the February 5, 2009 warning letter are considered to be resolved.
Electronic health records have the potential to reduce the incidence of medical errors, duplication of tests, and delays in treatment.
7 in 10 UK chronic pain sufferers delayed seeking medical advice during the COVID-19 pandemic, leaving them feeling increased levels of stress, anxiety and worry, new research from Boston Scientific has revealed.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Worth Audiology Pllc 10512 N 110th East Ave Ste 220, Owasso, OK 74055-6638 Ph: (918) 516-1919 | Worth Audiology Pllc 10512 N 110th East Ave Ste 220, Owasso, OK 74055-6638 Ph: (918) 516-1919 |
News Archive
Anacor Pharmaceuticals announced today that it has entered into a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation to provide up to $30 million in capital. Anacor used $6.6 million to repay the remaining obligations under its loan agreement with Lighthouse Capital Partners and expects to use the remainder of the capital to fund development activities related to AN2690, AN2728 and AN2898.
Taro Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has informed the Company that after a February 2011 re-inspection of its Canadian manufacturing facility, the site has an acceptable regulatory status. Therefore, the issues noted in the February 5, 2009 warning letter are considered to be resolved.
Electronic health records have the potential to reduce the incidence of medical errors, duplication of tests, and delays in treatment.
7 in 10 UK chronic pain sufferers delayed seeking medical advice during the COVID-19 pandemic, leaving them feeling increased levels of stress, anxiety and worry, new research from Boston Scientific has revealed.
› Verified 7 days ago